Sanofi’s AlphaMedix shows promising results in Phase 2 trial for GEP-NETs, meeting primary efficacy endpoints and demonstrating significant overall response rates. Secondary endpoints also show improvements in progression-free survival and overall survival. FDA grants Breakthrough Therapy Designation for treatment. Stock closes at $49.19. (Source: RTTNews)

Read more at Nasdaq.: Sanofi’s AlphaMedix Shows Strong Phase 2 Results For Advanced Neuroendocrine Tumor Treatment